Patents by Inventor Craig A. Rosen

Craig A. Rosen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vascular Endothelial Growth Factor 2
    Publication number: 20090192088
    Abstract: Disclosed is a human VEGF2 polypeptide and DNA(RNA) encoding such VEGF2 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist against such polypeptide. Such polypeptides may be combined with a suitable pharmaceutical carrier or diluent to provide diagnostic, therapeutic and/or prophylactic effects against various diseases. Also provided are methods of using the antibodies and antagonists to inhibit the action of VEGF2 for therapeutic purposes.
    Type: Application
    Filed: March 2, 2009
    Publication date: July 30, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jing-Shan Hu, Craig A. Rosen, Liang Cao
  • NEUTROKINE-ALPHA ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20090169565
    Abstract: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody.
    Type: Application
    Filed: February 26, 2009
    Publication date: July 2, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig A. Rosen
  • HEMCM42 NUCLEIC ACIDS
    Publication number: 20090148900
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.
    Type: Application
    Filed: November 26, 2008
    Publication date: June 11, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Craig A. Rosen, Gregory A. Endress
  • Interleukin-1 Beta Converting Enzyme Like Apoptosis Protease-3 and 4
    Publication number: 20090142329
    Abstract: Disclosed are human interleukin-1 ? converting enzyme like apoptosis proteases-3 and 4 and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Also provided are methods of using the polypeptides, for example, as an antitumor agent, and antiviral agent, and antibodies and antagonists against such polypeptides for example, for treating Alzheimer's disease, Parkinson's disease, rheumatoid arthritis and head injury. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases are also disclosed.
    Type: Application
    Filed: August 25, 2008
    Publication date: June 4, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: Wei-Wu He, Craig A. Rosen, Peter L. Hudson, Gregg A. Hastings
  • Antibodies that specifically bind to TL5
    Patent number: 7541441
    Abstract: The present invention relates to antibodies and related molecules that specifically bind to TL5. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including autoimmune disease, rheumatoid arthritis, graft rejection, graft vs. host disease, and lymphadenopathy. The invention also relates to nucleic acid molecules encoding anti-TL5 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer as well as immune system diseases and disorders including autoimmune disease, rheumatoid arthritis, graft rejection, graft vs.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: June 2, 2009
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, Steven M. Ruben
  • Human Tumor Necrosis Factor Receptor-Like 2
    Publication number: 20090131319
    Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
    Type: Application
    Filed: September 23, 2008
    Publication date: May 21, 2009
    Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.
    Inventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz, Sally Doreen Patricia Lyn, Mark Robert Hurle
  • Antibodies That Specifically Bind to Neurokinin B
    Publication number: 20090117043
    Abstract: The present invention relates to antibodies and related molecules that specifically bind to neurokinin B. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including pre-eclampsia, hypertension, inflammation, asthma, gastrointestinal disorders, anxiety, depression, addiction, or pain. The invention also relates to nucleic acid molecules encoding anti-neurokinin B antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
    Type: Application
    Filed: August 14, 2008
    Publication date: May 7, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, Steven M. Ruben
  • Methods of treating an injury to, or disorder of, the eye involving photoreceptor proliferation by administering VEGF2 antibodies
    Patent number: 7524501
    Abstract: The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: April 28, 2009
    Assignee: Human Genome Sciences, Inc.
    Inventors: Ralph Alderson, Robert Melder, Viktor Roschke, Steven M. Ruben, Craig A. Rosen
  • NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT
    Publication number: 20090104189
    Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.
    Type: Application
    Filed: September 12, 2008
    Publication date: April 23, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: GUO-LIANG YU, Reinhard Ebner, Jian Ni, Craig A. Rosen, Stephen Ullrich
  • Albumin Fusion Proteins
    Publication number: 20090105140
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Application
    Filed: July 10, 2008
    Publication date: April 23, 2009
    Inventors: Craig A. Rosen, William A. Haseltine
  • Albumin fusion proteins
    Patent number: 7521424
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: July 7, 2005
    Date of Patent: April 21, 2009
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
  • Albumin Fusion Proteins
    Publication number: 20090099073
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Application
    Filed: October 30, 2007
    Publication date: April 16, 2009
    Inventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Turner, Steven M. Ruben
  • Albumin Fusion Proteins
    Publication number: 20090093402
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Application
    Filed: October 30, 2007
    Publication date: April 9, 2009
    Applicants: Human Genome Sciences, Inc., Delta Biotechnology Limited
    Inventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Turner, Steven M. Ruben
  • Human Tumor Necrosis Factor Receptor-Like 2
    Publication number: 20090092608
    Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
    Type: Application
    Filed: September 30, 2008
    Publication date: April 9, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz
  • Antibodies that specifically bind to neurokinin B
    Patent number: 7514079
    Abstract: The present invention relates to antibodies and related molecules that specifically bind to neurokinin B. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including pre-eclampsia, hypertension, inflammation, asthma, gastrointestinal disorders, anxiety, depression, addiction, or pain. The invention also relates to nucleic acid molecules encoding anti-neurokinin B antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: April 7, 2009
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, Steven M. Ruben
  • Methods of inhibiting an immune response with anti-human endokine alpha antibodies
    Patent number: 7514081
    Abstract: The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods concerning TNF family-related disorders.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: April 7, 2009
    Assignee: Human Genome Sciences, Inc.
    Inventors: Guo-Liang Yu, Jian Ni, Craig A. Rosen
  • 44 Human Secreted Proteins
    Publication number: 20090088555
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.
    Type: Application
    Filed: November 20, 2008
    Publication date: April 2, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: David W. LaFleur, Steven M. Ruben, Craig A. Rosen, Paul A. Moore, Yanggu Shi, Hla Kyaw, Ying-Fei Wei
  • CD33-Like Protein
    Publication number: 20090081727
    Abstract: The present invention concerns a novel CD33-like protein. In particular, isolated nucleic acid molecules are provided encoding the CD33-like protein. Recombinant CD33-like polypeptides are also provided as are recombinant vectors and host cells. The invention further provides methods useful during tumor or inflammatory disease diagnosis or prognosis and therapeutic treatments targeting cells expressing CD33-like polypeptides.
    Type: Application
    Filed: January 25, 2008
    Publication date: March 26, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Craig A. Rosen
  • 123 Human Secreted Proteins
    Publication number: 20090082264
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.
    Type: Application
    Filed: April 13, 2007
    Publication date: March 26, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: Carrie L. Fischer, Craig A. Rosen, Daniel R. Soppet, Steven M. Ruben, Hla Kyaw, Yi Li, Zhizhen Zeng, David W. LaFleur, Paul A. Moore, Yanggu Shi, Henrik Olsen, Reinhard Ebner, Charles E. Birse
  • Albumin fusion proteins
    Patent number: 7507413
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: March 24, 2009
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, William A. Haseltine